About this item:

492 Views | 136 Downloads

Author Notes:

Reprint requests to: Matthew J. Ferris, MD, Department of Radiation Oncology, The Emory Clinic, 1365 Clifton Rd NE, Atlanta, GA 30322. Tel: (404) 778-3473; mjferri@emory.edu

Conflict of interest: none.

Subjects:

Research Funding:

Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and the National Institutes of Health/National Cancer Institute under award number P30CA138292.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Radiology, Nuclear Medicine & Medical Imaging
  • LOW-DOSE RADIOTHERAPY
  • ABDOMINAL NEUROBLASTOMA
  • MULTIMODALITY THERAPY
  • HOSPITAL EXPERIENCE
  • SURGICAL RESECTION
  • TUMOR-CONTROL
  • CHILDREN
  • SURVIVAL
  • IMPACT
  • TRANSPLANTATION

Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement

Show all authors Show less authors

Tools:

Journal Title:

International Journal of Radiation Oncology - Biology - Physics

Volume:

Volume 97, Number 4

Publisher:

, Pages 806-812

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Purpose: To report the influence of radiation therapy (RT) dose and surgical pathology variables on disease control and overall survival (OS) in patients treated for high-risk neuroblastoma at a single institution. Methods and Materials: We conducted a retrospective study of 67 high-risk neuroblastoma patients who received RT as part of definitive management from January 2003 until May 2014. Results: At a median follow-up of 4.5 years, 26 patients (38.8%) failed distantly; 4 of these patients also failed locally. One patient progressed locally without distant failure. Local control was 92.5%, and total disease control was 59.5%. No benefit was demonstrated for RT doses over 21.6 Gy with respect to local relapse–free survival (P=.55), disease-free survival (P=.22), or OS (P=.72). With respect to local relapse–free survival, disease-free survival, and OS, no disadvantage was seen for positive lymph nodes on surgical pathology, positive surgical margins, or gross residual disease. Of the patients with gross residual disease, 75% (6 of 8) went on to have no evidence of disease at time of last follow-up, and the 2 patients who failed did so distantly. Conclusions: Patients with high-risk neuroblastoma in this series maintained excellent local control, with no benefit demonstrated for radiation doses over 21.6 Gy, and no disadvantage demonstrated for gross residual disease after surgery, positive surgical margins, or pathologic lymph node positivity. Though the limitations of a retrospective review for an uncommon disease must be kept in mind, with small numbers in some of the subgroups, it seems that dose escalation should be considered only in exceptional circumstances.

Copyright information:

© 2016 Elsevier Inc.

Export to EndNote